ABN-Amro Stockbrokers is tipping Galen Pharmaceuticals as a good bet for investors. The Northern Ireland-based company is expected to achieve strong growth in all of its divisions in the medium term and could secure partners or make acquisitions in Europe and the US in the next 12 months.

The shares are currently trading below the sector average according to ABN-Amro. The brokers has set an end of year share price target of 910p, an increase of 35 per cent on the current share price. "We believe that Galen is the most attractive investment opportunity in the emerging pharmaceuticals segment of the sector, from both valuation and risk profile standpoints."